Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation

Roberto J Firpi; Haizhen Zhu; Giuseppe Morelli; Manal F Abdelmalek; Consuelo Soldevila-Pico; Victor I Machicao; Roniel Cabrera; Alan I Reed; Chen Liu; David R Nelson

doi:10.1002/lt.20532

Back

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation

Journal article

Peer reviewed

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation

Roberto J Firpi, Haizhen Zhu, Giuseppe Morelli, Manal F Abdelmalek, Consuelo Soldevila-Pico, Victor I Machicao, Roniel Cabrera, Alan I Reed, Chen Liu and David R Nelson

Liver transplantation, Vol.12(1), pp.51-57

01/2006

DOI: 10.1002/lt.20532

PMID: 16382464

View Online

Abstract

Cyclosporine is an immunosuppressive agent widely used in the management of liver transplant recipients. Cyclosporine has been shown to have antiviral activities against HIV, herpes simplex, and vaccinia viruses. The aim of this study was to determine the effect of Cyclosporine in viral clearance in the liver transplant recipients during therapy with combination of interferon and ribavirin, and to determine the anti-viral potential of Cyclosporine in vitro. Immunosuppression consisted of either Cyclosporine or Tacrolimus-based therapy. Both groups received therapy with interferon and ribavirin for 48 weeks when evidence of progressive histologic disease was determined. We found that subjects on Cyclosporine-based immunosuppression (n = 56) had a higher sustained virological response of 46% compared to 27% in the patients on Tacrolimus-based therapy (n = 59, P = 0.03). In vitro studies were performed to evaluate the antiviral effect of Cyclosporine in the replicon system. These studies showed that Cyclosporine inhibits hepatitis C viral replication in a dose-dependent manner. Combination of Cyclosporine with interferon showed additive effect, and its function is independent of interferon signaling pathways. In conclusion, Cyclosporine may offer an advantage to Tacrolimus in those patients undergoing interferon-based therapy and should be studied in a prospective randomized trial.

Liver Failure - etiology

Follow-Up Studies

Liver Transplantation - adverse effects

Cyclosporine - pharmacology

Humans

Immunosuppressive Agents - therapeutic use

Middle Aged

Postoperative Complications - prevention & control

Secondary Prevention

Hepatitis C, Chronic - complications

Liver Transplantation - methods

Tacrolimus - pharmacology

Adult

Retrospective Studies

Postoperative Complications - drug therapy

Immunosuppressive Agents - pharmacology

Hepacivirus - drug effects

Hepacivirus - isolation & purification

Graft Rejection - prevention & control

Graft Survival

Treatment Outcome

Hepatitis C, Chronic - drug therapy

Cyclosporine - therapeutic use

Tacrolimus - therapeutic use

In Vitro Techniques

Liver Failure - surgery

Details

Title: Subtitle: Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation
Creators: Roberto J Firpi - Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Section of Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610-0214, USA. firpirj@medicine.ufl.edu
Haizhen Zhu
Giuseppe Morelli
Manal F Abdelmalek
Consuelo Soldevila-Pico
Victor I Machicao
Roniel Cabrera
Alan I Reed
Chen Liu
David R Nelson
Resource Type: Journal article
Publication Details: Liver transplantation, Vol.12(1), pp.51-57
DOI: 10.1002/lt.20532
PMID: 16382464
NLM abbreviation: Liver Transpl
ISSN: 1527-6465
eISSN: 1527-6473
Publisher: United States
Grant note: RR0082 / NCRR NIH HHS
Language: English
Date published: 01/2006
Academic Unit: Accounting; Surgery
Record Identifier: 9984051754202771

Metrics

21 Record Views

133 Times Cited - Web of Science

See more details